OR WAIT null SECS
Making the Grade: The Importance of Using the Correct Excipient Grade in Drug Products
With an ever-growing market driving technological advances, there is always work to be done in drug manufacturing.
Advanced oral dosage forms allow for modulation of controlled- and sustained-release profiles.
Packaging and packaging line innovations are addressing the industry’s growing use of biologics.
What are the lessons gleaned from a product’s E&L lifetime?
There are considerations companies may want to consider before seeking out a service provider.
The Biosimilars Landscape
April 17, 2024
Wenyu Zhang, PhD, addressed new trends in the aseptic industry and the chief concerns companies should keep in mind while weighing their options, at INTERPHEX 2024.
Susan Schniepp, distinguished fellow, Regulatory Compliance Associates, and co-chair of board of directors, Parenteral Drug Association, demonstrates QMS impact on quality maturity at INTERPHEX.
At INTERPHEX 2024, Pharmaceutical Technology sat down with Christa Myers of CRB Group and Nadiyra Walker Speight of Fujifilm Diosynth Biotechnologies to discuss implementation of Annex 1.
The Xcellerex magnetic mixer, single-use mixing system was designed to address challenges in large-scale mAb, vaccine, and genomic medicine manufacturing processes.
Former FDA drug investigator, Daniel Roberts, discusses the importance of updating process validation and maintaining proper data integrity at a keynote session during INTERPHEX.
April 16, 2024
The airlock solution for cleanrooms offers contamination controls for a highly controlled environment.
At INTERPHEX, Bill Whitford, Strategic Solutions leader at Arcadis, discusses the progress made in 3D bioprinting toward commercial biologics production.
WMFTS has launched WMArchitect, a single-use product line that offers ready-to-use single-use assemblies and custom-designed workflows for biopharma fluid management.
April 15, 2024
C3TI will promote CDER’s clinical trial innovation activities both internally and externally.
April 12, 2024
The agency’s risk assessment committee has concluded that available evidence has not been found that supports a causal association between glucagon-like peptide-1 receptor agonists and self-harming thoughts and actions.